ATEC
Alphatec Holdings, Inc.Price & Indicators
Blended from price, positioning & fundamentals · daily-close · not investment advice.
TL;DR.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Technicals
trend & momentum for long-term holders NeutralIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from its earnings releases, calls, and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Free cash flow non-GAAP | $3M | full year | — |
| Non-GAAP adjusted EBITDA non-GAAP | $33M | Quarter Ended December 31, 2025 | — |
| Non-GAAP adjusted EBITDA margin non-GAAP | 16% | Quarter Ended December 31, 2025 | — |
| average revenue per procedure growth | 2% | Full Year Ended December 31, 2025 | — |
| cash balance | $161M | as of December 31, 2025 | — |
| surgical volume growth | 24% | Full Year Ended December 31, 2025 | — |
Figures exactly as the company stated them · click a metric with a to chart its history · period links open the stating document · "call" marks figures stated on the earnings call, "filing" figures stated in the 10-K/10-Q · YoY needs the prior-year figure on file
Versus peers
Medical Devices — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
ATEC
this stock
Alphatec Holdings, Inc.
|
$1.37B | -57.6% | -15.4% | — | 8.0% |
|
ABT
Abbott Laboratories
|
$166.17B | -23.5% | +5.7% | 26.7 | 1.3% |
|
SYK
Stryker Corp
|
$125.18B | -6.8% | +11.2% | 37.8 | 1.6% |
|
MDT
Medtronic plc
|
$106.49B | -12.7% | +8.4% | 22.3 | 1.4% |
|
BSX
Boston Scientific Corp
|
$67.09B | -52.7% | +5.5% | 18.9 | 2.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| ATEC | +1.0% | +16.2% | -60.7% | +3.1% | -57.6% |
| SPY | +1.4% | -1.3% | +8.0% | -0.3% | +9.2% |
| vs SPY | -0.4% | +17.4% | -68.7% | +3.4% | -66.8% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.